Puma Submits sNDA for Neratinib Combo Therapy for HER2-Positive Metastatic Breast Cancer
July 12th 2019Puma Biotechnology submitted a supplemental New Drug Application to the FDA for neratinib (Nerylnx) in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Read More